Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats

Inflammopharmacology

Volumn 15, Issue 5, 2007, Pages 188-195

  Dudhgaonkar, S P ^a   Tandan, S K ^a   Kumar, D ^a   Raviprakash, V ^a   Kataria, M ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Colitis; COX 2; Inflammation; iNOS; Interaction; Rats

Indexed keywords

AMINOGUANIDINE; BENCYCLANE; CATALASE; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; NITRATE; NITRITE; ROFECOXIB; SUPEROXIDE DISMUTASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; INFLAMMATION; LIPID PEROXIDATION; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; ULCERATIVE COLITIS;

ANIMALS; CATALASE; COLITIS; COLON; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GUANIDINES; INTESTINE, LARGE; LACTONES; LIPID PEROXIDATION; MALE; NITRATES; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PEROXIDASE; RATS; RATS, INBRED STRAINS; SULFONES; SUPEROXIDE DISMUTASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35349024376     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-007-1603-3     Document Type: Article

References (61)

1. Ademoglu, E., Erbil, Y., Tam, B., et al. (2004). Do vitamin E and selenium have beneficial effects on trinitrobenzenesulfonic acid-induced experimental colitis? Dig. Dis. Sci. 49, 102-108.
2. Aebi, H.E. (1983). Catalase. In: Methods of Enzymatic Analysis, Bergemeyer, H.U. (Ed.), pp. 273-285. Weinheim, V.C.H., Basel.
3. Ajuebor, M.N., Singh, A., Wallace, J.L. (2000). Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol. - Gastrointest. Liver Physiol. 279, G238-G244.
4. Alderton, W.K., Cooper, C.E., Knowles, R.G. (2001). Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357, 593-615.
5. Carty, E., De Brabander, M., Feakin, R.M. et al. (2000). Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 46, 487-492.
6. Cetinkaya, A., Bulbuloglu, E., Kurutas, E.B. et al. (2005). Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J. Exp. Med. 206, 131-139.
7. Cosme, R., Lublin, D., Takafuji, V. et al. (2000). Prostanoids in human colonic mucosa: effects of inflammation on PGE(2) receptor expression. Hum. Immunol. 61, 684-696.
8. Cuzzocrea, S., Mazzon, E., Serraino, I. et al. (2001). Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur. J. Pharmacol. 431, 91-102.
9. Dieter, P., Hempel, U., Kamionka, S., et al. (1999). Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides. Mediators Inflamm. 8, 295-303.
10. Dijkstra, G., Moshage, H., van Dullemen, H.M., et al. (1998). Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J. Pathol. 186, 416-421.
11. Dryden, G.W. Jr., Deaciuc, I., Arteel, G., et al. (2005). Clinical implications of oxidative stress and antioxidant therapy. Curr. Gastroenterol. Rep. 7, 308-316.
12. Fiocchi, C. (1998). Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115, 182-205.
13. Freitas, J., Farricha, V., Nascimento, I., et al. (2002). Rofecoxib: a possible cause of acute colitis. J. Clin. Gastroenterology 34, 451-453.
14. Gould, S.R. (1975). Letter: Prostaglandins, ulcerative colitis, and sulphasalazine. Lancet 2, 988.
15. Guo, X., Liu, E.S., Ko, J.K., et al. (2001). Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur. J. Pharmacol. 411, 193-203.
16. Hendel, J., Nielsen, O.H. (1997). Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am. J. Gastroenterol. 92, 1170-1173.
17. Hendrickson, B.A., Gokhale, R., Cho, J.H. (2002). Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 15, 79-94.
18. Hokari, R., Kato, S., Matsuzaki, K. et al. (2001). Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis. Free Radic. Biol. Med. 31, 153-163.
19. Kankuri, E., Vaali, K., Knowles, R.G. et al. (2001). Suppression of acute experimental colitis by a highly selective inducible Nitric-oxide synthase inhibitor, N-[3-(Aminomethyl benzyl] acetamidine. J. Pharmacol. Exp. Ther. 298, 1128-1132.
20. Kankuri, E., Vaali, K., Korpela, R. et al. (2001). Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflamm. 25, 301-10.
21. Kankuri, E. (2002). On the role of inducible enzymes iNOS and COX-2 in colitis. Academic dissertation submitted to Institute of Biomedicine, University of Helsinki.
22. Karmeli, F., Cohen, P., Rachmilewitz, D. (2000). Cyclooxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur. J. Gastroesterol. Hepatol. 12, 223-231.
23. Kimura, H,. Hokari, R., Miura, S., et al. (1998). Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 42, 180-187.
24. Kimura, H., Miura, S., Shigematsu, T., et al. (1997). Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Dig. Dis. Sci. 42, 1047-1054.
25. Klebenoff, S.J. (1965). Inactivation of estrogen by rat uterine preparation. Endocrinology 76, 301-311.
26. Kruidenier, L., Kuiper, I., Lamers, C.B., et al. (2003). Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J. Pathol. 201, 28-36.
27. Leonard, N., Bishop, A.E., Polak, J.M., et al. (1998). Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment. J. Clin. Pathol. 51, 750-3.
28. Lesch, C.A., Kraus, E.R., Sanchez, B., et al. (1999). Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis. Meth. Findings Exp. Clin. Pharmacol. 21, 99-104.
29. Lundberg, J.O., Hellstrom, P.M., Lundberg, J.M., et al. (1994). Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 344, 1673-1674.
30. Madesh, M., Balasubramanium, K.A. (1998). Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. Indian J. Biochem. Biophys. 35, 184-188.
31. Menchen, L.A., Colon, A.L., Moro, M.A., et al. (2001). N-(3-(aminome thyl)benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Life Sci. 69, 479-91.
32. Martin, A.R., Villegas, I., Casa, C.L., et al. (2003). The cyclooxygenase-2 inhibitor, rofecoxib , attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur. J. Pharmacol. 481, 281-291.
33. Matuk, R., Crawford, J., Abreu, M.T., et al. (2004). The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10, 352-356.
34. McCafferty, D.M., Miampamba, M/, Sihota, E., et al. (1999). Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut 45, 864-873.
35. McCafferty, D.M., Mudgett, J.S., Swain, M.G., et al. (1997). Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 112, 1022-1027.
36. Morris, G.P., Beck, P.L., Heriidge, M.S., et al. (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96, 795-803.
37. Murthy, S., Cooper, H.S., Yoshitake, H., et al. (1999). Combination therapy of pentoxifylline and TNF-alpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment. Pharmacol. Ther. 13, 251-260.
38. Negoro, K., Kinouchi, Y., Hiwatashi, N., et al. (1999). Crohn's disease is associated with novel polymorphism in the 5′ flanking region of tumor necrosis factor gene. Gastroenterology 117, 1062-1068.
39. Newberry, R.D., Stenson, W.F., Lorenz, R.G. (1999). Cyclooxygenase-2 dependent arachidonic acid metabolites are essential modulators of the initial immune response to dietary antigen. Nature Med. 5, 900-906.
40. Present, D.H., Rutgeerts, P., Targan, S., et al. (1999). Infliximab for the treatment of fistulas in patients with Crohn's disease. New Eng. J. Med. 340, 1398-1405.
41. Raab, Y., Sundberg, C., Hallgren, R., et al. (1995). Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am. J. Gastroenterol. 90, 614-620.
42. Rachmilewitz, D., Karmeli, F., Okon, E., et al. (1995). Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 37, 247-255.
43. Ricart, E., Panaccione, R., Loftus, E.V., et al. (1999). Successful management of Crohn's disease of the ileonal pouch with infliximab. Gastroenterology 117, 429-432.
44. Roberts, P.J., Morgan, K., Miller, R., et al. (2001). Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 48, 468-472.
45. Roediger, W.E., Lawson, M.J., Nance, S.H., et al. (1986). Detectable colonic nitrite levels in inflammatory bowel disease - mucosal or bacterial malfunction? Digestion 35, 199-204.
46. Salvemini, D., Misko, T.P., Masferrer, J.L., et al. (1993). Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA 90, 7240-7244.
47. Salvemini, D., Wang, Z.Q., Wyatt, P.S., et al. (1996). Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw in inflammation. Br. J. Pharmacol. 118, 829-838.
48. Sastry, K.V.H., Moudgal, R.P., Mohan, J., et al. (2002). Spectrophotometric determination of serum nitrite and nitrate by copper cadmium alloy. Anal. Biochem. 306, 79-82.
49. Shafiq-Ur-Rehman. (1984). Lead induced regional lipid peroxidation in brain. Toxicol. Lett. 21, 333-337.
50. Singer. I.I., Kawka, D.W., Schloemann, S., et al. (1998). Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115, 297-306.
51. Singer, I.I., Kawka, D.W., Scott, S., et al. (1996). Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111, 871-885.
52. Singh, V.P., Patil, C.S., Jain, N.K., et al. (2003). Effect of nimesulide on acetic acid- and leukotriene-induced inflammatory bowel disease in rats. Prost. Lipid Mediators 71, 163-175.
53. Tardieu, D., Jaeg, J.P., Deloly, A., et al. (2000). The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy30 deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21, 973-976.
54. Tomilson, A., Appleton, I., Moore, A.R., et al. (1994). Cyclooxygenase and nitric oxide synthase isoforms in rat carrageenan-induced pleurisy. Br. J. Pharmacol. 113, 693-698.
55. Vane, J.R., Mitchell, J.A., Appleton, I., et al. (1994). Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc. Natl. Acad. Sci. USA 91, 2046-2050.
56. Weinberg, J.B. (2000). Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol. Res. 22, 319-341.
57. Whittle, B.J. and Vane, J.R. (1987). Prostanoids as regulators of gastrointestinal function. In: Physiology of Gastrointestinal Tract, Johnson LR (Ed), pp. 143-180. Raven Press, New York..
58. Winter, C.A., Risley, E.A., Nuss, G.W. (1962). Carrageenan-induced edema in hind paw of rats as an assay for anti-inflammatory drugs. Proc. Soc. Biol. Med. 111, 544-547.
59. Yue, G., Lai, P.S., Yin, K., et al. (2001). Colon epithelial cell death in 2,4,6- trinitrobenzenesulfonic acid-induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production. J. Pharmacol. Exp. Ther. 297, 915-925.
60. Zhang, L., Lu, Y.M., Dong, X.Y. (2004). Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chinese J. Dig. Dis. 5, 110-114.
61. Zingarelli, B., Szabo, C., Salzman, A.L. (1999). Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 45, 199-209.